Monitor the company's daily trading volume and any subsequent 8-K or prospectus supplement filings for actual share sales under the ATM program. The large authorized amount ($100M vs $153M market cap) creates persistent overhang; any material volume of sales would likely pressure the stock price.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Sep 1 $1.13entry
- T+1 · 3mo ago +3.54%α +3.10% · $1.17
- T+5 · 2mo ago +84.07%α +83.99% · $2.08
- T+20 · 7w ago +104.87%α +103.69% · $2.32
- T+53 · todayOpen
- T+60 · in 8d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Indaptus Therapeutics entered into an amended and restated at-the-market offering agreement with H.C. Wainwright, enabling the sale of up to $100 million in common stock. This filing, combined with the prospectus supplement filed the prior day, formalizes a significant capital raise capacity for the clinical-stage biotech. The potential for substantial dilution overhangs the stock, though the company has no obligation to sell any shares.
Key Facts
- Indaptus entered into an Amended and Restated At the Market Offering Agreement with H.C. Wainwright for up to $100,000,000 in common stock.
- The agreement amends and restates the prior June 1, 2022 agreement.
- H.C. Wainwright will receive a 3.0% placement fee on shares sold as agent.
- The company filed a related prospectus supplement on August 31, 2026.
- As of August 26, 2026, the last reported sale price was $1.14 per share.
- Prior sales under the original agreement totaled approximately $2.74 million (520,000 shares at ~$2.34M and 5,428 shares at ~$0.4M).
Financial Impact
Up to $100,000,000 in potential common stock sales, creating significant dilution risk for existing shareholders.
Risk Factors
- Significant dilution if the full $100 million ATM is utilized.
- Stock price pressure from continuous selling into the market.
- Clinical-stage biotech with no approved products, making equity financing a primary capital source.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-040926 |
| Exhibit: ex5-1.htm | 0001493152-26-040926 |
| Document: form8-k.htm | 0001493152-26-040926 |
| Document: 0001493152-26-040926-index-headers.html | 0001493152-26-040926 |
| Document: 0001493152-26-040926-index.html | 0001493152-26-040926 |
| Document: 0001493152-26-040926.txt | 0001493152-26-040926 |
Track record
20 reports on INDP
4 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +59.35% at T+20 after the Jul 20, 2026 report. 6 of 9 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.17 Now $3.45 +8.83% settles Dec 15
- Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 22, 202625d ago SC 13D/A Neutral 3/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 21, 202626d ago SC 13D/A Neutral 4/10 Entry $2.99 Now $3.45 +15.38% settles Nov 19
- Oct 20, 202627d ago 8-K Bearish 6/10 Entry $3.16 Now $3.45 −9.18% settles Nov 18
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $2.30 to $3.31 Now $3.45 +50.00% ▲ +43.70% +42.43% vs SPY
- Sep 9, 20269w ago 8-K Bearish 7/10 Entry $2.56 to $2.37 Now $3.45 −34.77% ▲ +7.42% +9.55% vs SPY
- Sep 4, 202610w ago 424B5 Bearish 6/10 Entry $1.85 to $2.59 Now $3.45 −86.49% ▼ −40.00% −38.29% vs SPY
- Sep 1, 202610w ago 8-K Bearish 5/10 Viewing Entry $1.13 to $2.32 Now $3.45 −205.31% ▼ −104.87% −103.69% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers